Alan Mast - Publications

Affiliations: 
University of Tennessee Health Science Center, Memphis, TN, United States 
Area:
Pathology, Biochemistry

66 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Wood JP, Baumann Kreuziger LM, Desai UR, Mast AE. Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins. British Journal of Haematology. PMID 27301751 DOI: 10.1111/bjh.14182  1
2016 Cable RG, Brambilla D, Glynn SA, Kleinman S, Mast AE, Spencer BR, Stone M, Kiss JE. Effect of iron supplementation on iron stores and total body iron after whole blood donation. Transfusion. PMID 27232535 DOI: 10.1111/trf.13659  1
2016 Peterson JA, Maroney SA, Mast AE. Targeting TFPI for hemophilia treatment. Thrombosis Research. 141: S28-30. PMID 27207418 DOI: 10.1016/S0049-3848(16)30359-0  1
2016 Mast AE, Bialkowski W, Bryant BJ, Wright DJ, Birch R, Kiss JE, D'Andrea P, Cable RG, Spencer BR. A randomized, blinded, placebo-controlled trial of education and iron supplementation for mitigation of iron deficiency in regular blood donors. Transfusion. PMID 26813849 DOI: 10.1111/trf.13469  1
2015 Ellery PE, Maroney SA, Cooley BC, Luyendyk JP, Zogg M, Weiler H, Mast AE. A balance between TFPI and thrombin-mediated platelet activation is required for murine embryonic development. Blood. 125: 4078-84. PMID 25954015 DOI: 10.1182/blood-2015-03-633958  1
2015 Kiss JE, Brambilla D, Glynn SA, Mast AE, Spencer BR, Stone M, Kleinman SH, Cable RG. Oral iron supplementation after blood donation: a randomized clinical trial. Jama. 313: 575-83. PMID 25668261 DOI: 10.1001/jama.2015.119  1
2015 Annen K, Delaney M, Leitch D, Mast AE. The health implications of low hemoglobin deferral in infrequent blood donors. Transfusion. 55: 86-90. PMID 25082192 DOI: 10.1111/trf.12801  1
2015 Maroney SA, Mast AE. New insights into the biology of tissue factor pathway inhibitor Journal of Thrombosis and Haemostasis. 13: S200-S207. DOI: 10.1111/jth.12897  1
2014 Wood JP, Ellery PE, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood. 123: 2934-43. PMID 24620349 DOI: 10.1182/blood-2013-11-512764  1
2014 Mast AE. Low hemoglobin deferral in blood donors. Transfusion Medicine Reviews. 28: 18-22. PMID 24332843 DOI: 10.1016/j.tmrv.2013.11.001  1
2014 Wood JP, Ellery PE, Maroney SA, Mast AE. Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-α but not for cell surface-associated tissue factor pathway inhibitor. Arteriosclerosis, Thrombosis, and Vascular Biology. 34: 169-76. PMID 24233490 DOI: 10.1161/ATVBAHA.113.302655  1
2014 Ellery PE, Maroney SA, Martinez ND, Wickens MP, Mast AE. Translation of human tissue factor pathway inhibitor-β mRNA is controlled by alternative splicing within the 5' untranslated region. Arteriosclerosis, Thrombosis, and Vascular Biology. 34: 187-95. PMID 24233486 DOI: 10.1161/ATVBAHA.113.302660  1
2013 Sosa IR, Ellery P, Mast A, Neff AT, Gailani D. Acquired factor V deficiency in a patient without evidence of a classical inhibitor Haemophilia. 20. PMID 24118596 DOI: 10.1111/hae.12280  1
2013 Maroney SA, Hansen KG, Mast AE. Cellular expression and biological activities of alternatively spliced forms of tissue factor pathway inhibitor. Current Opinion in Hematology. 20: 403-9. PMID 23839295 DOI: 10.1097/MOH.0b013e3283634412  1
2013 Kiss JE, Steele WR, Wright DJ, Mast AE, Carey PM, Murphy EL, Gottschall JL, Simon TL, Cable RG. Laboratory variables for assessing iron deficiency in REDS-II Iron Status Evaluation (RISE) blood donors. Transfusion. 53: 2766-75. PMID 23617531 DOI: 10.1111/trf.12209  1
2013 Mast AE, Schlumpf KS, Wright DJ, Johnson B, Glynn SA, Busch MP, Olbina G, Westerman M, Nemeth E, Ganz T. Hepcidin level predicts hemoglobin concentration in individuals undergoing repeated phlebotomy. Haematologica. 98: 1324-30. PMID 23445875 DOI: 10.3324/haematol.2012.070979  1
2013 Brugnara C, Adamson J, Auerbach M, Kane R, Macdougall I, Mast A. Iron deficiency: what are the future trends in diagnostics and therapeutics? Clinical Chemistry. 59: 740-5. PMID 23150055 DOI: 10.1373/clinchem.2012.182071  1
2012 Mast AE, Field JJ. Iron chelation therapy in patients with transfusion-dependent myelodysplastic syndrome. Transfusion. 52: 2078-80. PMID 23110731 DOI: 10.1111/j.1537-2995.2012.03894.x  1
2012 Mast AE, Steele WR, Johnson B, Wright DJ, Cable RG, Carey P, Gottschall JL, Kiss JE, Simon TL, Murphy EL. Population-based screening for anemia using first-time blood donors. American Journal of Hematology. 87: 496-502. PMID 22460662 DOI: 10.1002/ajh.23171  1
2012 Maroney SA, Mast AE. Platelet tissue factor pathway inhibitor modulates intravascular coagulation. Thrombosis Research. 129: S21-2. PMID 22425319 DOI: 10.1016/j.thromres.2012.02.023  1
2012 Wolberg AS, Mast AE. Tissue factor and factor VIIa--hemostasis and beyond. Thrombosis Research. 129: S1-4. PMID 22417944 DOI: 10.1016/j.thromres.2012.02.017  1
2012 Maroney SA, Cooley BC, Ferrel JP, Bonesho CE, Nielsen LV, Johansen PB, Hermit MB, Petersen LC, Mast AE. Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia. Proceedings of the National Academy of Sciences of the United States of America. 109: 3927-31. PMID 22355108 DOI: 10.1073/pnas.1119858109  1
2012 Mast AE, Lee TH, Schlumpf KS, Wright DJ, Johnson B, Carrick DM, Cable RG, Kiss JE, Glynn SA, Steele WR, Murphy EL, Sacher R, Busch MP. The impact of HFE mutations on haemoglobin and iron status in individuals experiencing repeated iron loss through blood donation*. British Journal of Haematology. 156: 388-401. PMID 22118647 DOI: 10.1111/j.1365-2141.2011.08952.x  1
2012 Cable RG, Glynn SA, Kiss JE, Mast AE, Steele WR, Murphy EL, Wright DJ, Sacher RA, Gottschall JL, Tobler LH, Simon TL. Iron deficiency in blood donors: the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion. 52: 702-11. PMID 22023513 DOI: 10.1111/j.1537-2995.2011.03401.x  1
2012 Carey PM, High PM, Schlumpf KS, Johnson BR, Mast AE, Rios JA, Simon TL, Wilkinson SL. Donation return time at fixed and mobile donation sites. Transfusion. 52: 127-33. PMID 21745215 DOI: 10.1111/j.1537-2995.2011.03235.x  1
2011 Mast AE. Alternatively spliced tissue factor pathway inhibitor: functional implications. Frontiers in Bioscience (Scholar Edition). 3: 1457-62. PMID 21622281  1
2011 Gilbert GE, Mast AE. Curbing an inhibitor for hemostasis. Blood. 117: 5277-8. PMID 21596863 DOI: 10.1182/blood-2011-03-342725  1
2011 Maroney SA, Cooley BC, Ferrel JP, Bonesho CE, Mast AE. Murine hematopoietic cell tissue factor pathway inhibitor limits thrombus growth. Arteriosclerosis, Thrombosis, and Vascular Biology. 31: 821-6. PMID 21233452 DOI: 10.1161/ATVBAHA.110.220293  1
2011 Maroney SA, Mast AE. Tissue factor pathway inhibitor and bacterial infection Journal of Thrombosis and Haemostasis. 9: 119-121. PMID 21210950 DOI: 10.1111/j.1538-7836.2010.04111.x  1
2011 Zaman FS, Mast AE, Hall CL. Evaluating surface bound rTFPI through an in vitro model of vessel wall injury. Thrombosis Research. 127: 149-53. PMID 21195461 DOI: 10.1016/j.thromres.2010.11.009  1
2011 Cable RG, Glynn SA, Kiss JE, Mast AE, Steele WR, Murphy EL, Wright DJ, Sacher RA, Gottschall JL, Vij V, Simon TL. Iron deficiency in blood donors: analysis of enrollment data from the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion. 51: 511-22. PMID 20804527 DOI: 10.1111/j.1537-2995.2010.02865.x  1
2010 White TA, Johnson T, Zarzhevsky N, Tom C, Delacroix S, Holroyd EW, Maroney SA, Singh R, Pan S, Fay WP, van Deursen J, Mast AE, Sandhu GS, Simari RD. Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis. Blood. 116: 1787-94. PMID 20516367 DOI: 10.1182/blood-2009-10-250910  1
2010 Scott EA, Schlumpf KS, Mathew SM, Mast AE, Busch MP, Gottschall JL. Biospecimen repositories: are blood donors willing to participate? Transfusion. 50: 1943-50. PMID 20456705 DOI: 10.1111/j.1537-2995.2010.02667.x  1
2010 Mast AE, Schlumpf KS, Wright DJ, Custer B, Spencer B, Murphy EL, Simon TL. Demographic correlates of low hemoglobin deferral among prospective whole blood donors. Transfusion. 50: 1794-802. PMID 20412525 DOI: 10.1111/j.1537-2995.2010.02649.x  1
2010 Maroney SA, Ellery PE, Mast AE. Alternatively spliced isoforms of tissue factor pathway inhibitor. Thrombosis Research. 125: S52-6. PMID 20176395 DOI: 10.1016/j.thromres.2010.01.038  1
2008 Mast AE, Foster TM, Pinder HL, Beczkiewicz CA, Bellissimo DB, Murphy AT, Kovacevic S, Wroblewski VJ, Witcher DR. Behavioral, biochemical, and genetic analysis of iron metabolism in high-intensity blood donors. Transfusion. 48: 2197-204. PMID 18657084 DOI: 10.1111/j.1537-2995.2008.01823.x  1
2008 Maroney SA, Ferrel JP, Collins ML, Mast AE. Tissue factor pathway inhibitor-gamma is an active alternatively spliced form of tissue factor pathway inhibitor present in mice but not in humans. Journal of Thrombosis and Haemostasis : Jth. 6: 1344-51. PMID 18503630 DOI: 10.1111/j.1538-7836.2008.03033.x  1
2008 Maroney SA, Mast AE. Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society For Haemapheresis. 38: 9-14. PMID 18261960 DOI: 10.1016/j.transci.2007.12.001  1
2008 Mast AE, Blinder MA, Dietzen DJ. Reticulocyte hemoglobin content. American Journal of Hematology. 83: 307-10. PMID 18027835 DOI: 10.1002/ajh.21090  1
2008 Maroney SA, Cooley BC, Sood R, Weiler H, Mast AE. Combined tissue factor pathway inhibitor and thrombomodulin deficiency produces an augmented hypercoagulable state with tissue-specific fibrin deposition Journal of Thrombosis and Haemostasis. 6: 111-117. PMID 17973652 DOI: 10.1111/j.1538-7836.2007.02817.x  1
2007 Timmer JC, Enoksson M, Wildfang E, Zhu W, Igarashi Y, Denault JB, Ma Y, Dummitt B, Chang YH, Mast AE, Eroshkin A, Smith JW, Tao WA, Salvesen GS. Profiling constitutive proteolytic events in vivo. The Biochemical Journal. 407: 41-8. PMID 17650073 DOI: 10.1042/BJ20070775  1
2007 Maroney SA, Haberichter SL, Friese P, Collins ML, Ferrel JP, Dale GL, Mast AE. Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood. 109: 1931-7. PMID 17082321 DOI: 10.1182/blood-2006-07-037283  1
2006 Chandiwal A, Zaman FS, Mast AE, Hall CL. Factor Xa inhibition by immobilized recombinant tissue factor pathway inhibitor. Journal of Biomaterials Science. Polymer Edition. 17: 1025-37. PMID 17094640 DOI: 10.1163/156856206778366013  1
2006 Maroney SA, Cunningham AC, Ferrel J, Hu R, Haberichter S, Mansbach CM, Brodsky RA, Dietzen DJ, Mast AE. A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression. Journal of Thrombosis and Haemostasis : Jth. 4: 1114-24. PMID 16689766 DOI: 10.1111/j.1538-7836.2006.01873.x  1
2006 Donahue BS, Gailani D, Mast AE. Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass Journal of Thrombosis and Haemostasis. 4: 1011-1016. PMID 16689752 DOI: 10.1111/j.1538-7836.2006.01896.x  1
2006 Sood R, Kalloway S, Mast AE, Hillard CJ, Weiler H. Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells. Blood. 107: 3173-80. PMID 16380449 DOI: 10.1182/blood-2005-10-4111  1
2005 Sood R, Kalloway S, Mast AE, Weiler H. Thrombophilia and pregnancy failure: Feto-maternal interactions in the vascular bed of the placenta Thrombosis Research. 115: 92-94. PMID 15790167  1
2004 Raybagkar DA, Patchipulusu S, Mast AE, Hall CL. In vitro flow evaluation of recombinant tissue factor pathway inhibitor immobilized on collagen impregnated Dacron. Asaio Journal (American Society For Artificial Internal Organs : 1992). 50: 301-5. PMID 15307537  1
2003 Dietzen DJ, Jack GG, Page KL, Tetzloff TA, Hall CL, Mast AE. Localization of tissue factor pathway inhibitor to lipid rafts is not required for inhibition of factor VIIa/tissue factor activity. Thrombosis and Haemostasis. 89: 65-73. PMID 12540955 DOI: 10.1267/THRO03010065  1
2002 Mast AE, Acharya N, Malecha MJ, Hall CL, Dietzen DJ. Characterization of the association of tissue factor pathway inhibitor with human placenta. Arteriosclerosis, Thrombosis, and Vascular Biology. 22: 2099-104. PMID 12482841 DOI: 10.1161/01.ATV.0000042456.84190.F0  1
2002 Cunningham AC, Hasty KA, Enghild JJ, Mast AE. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8. The Biochemical Journal. 367: 451-8. PMID 12117418 DOI: 10.1042/BJ20020696  1
2002 Lockett JM, Mast AE. Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor. Biochemistry. 41: 4989-97. PMID 11939795 DOI: 10.1021/bi016058n  1
2002 Mast AE, Blinder MA, Lu Q, Flax S, Dietzen DJ. Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. Blood. 99: 1489-91. PMID 11830506 DOI: 10.1182/blood.V99.4.1489  1
2002 Chandiwal A, Mast AE, Hall CL. Assessment of the efficacy of tissue factor pathway inhibitor (TFPI) immobilized on glass slides to inhibit factor Xa under flow conditions Annual International Conference of the Ieee Engineering in Medicine and Biology - Proceedings. 1: 617-618.  1
2000 Mast AE, Stadanlick JE, Lockett JM, Dietzen DJ, Hasty KA, Hall CL. Tissue factor pathway inhibitor binds to platelet thrombospondin-1. The Journal of Biological Chemistry. 275: 31715-21. PMID 10922378 DOI: 10.1074/jbc.M006595200  1
1999 Mast AE, Stadanlick JE, Lockett JM, Dietzen DJ. Solvent/detergent-treated plasma has decreased antitrypsin activity and absent antiplasmin activity. Blood. 94: 3922-7. PMID 10572109  1
1998 Mast AE, Blinder MA, Gronowski AM, Chumley C, Scott MG. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations Clinical Chemistry. 44: 45-51. PMID 9550557  1
1996 Mast AE, Broze GJ. Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase Blood. 87: 1845-1850. PMID 8634431  1
1995 Warshawsky I, Bu G, Mast A, Saffitz JE, Broze GJ, Schwartz AL. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo Journal of Clinical Investigation. 95: 1773-1781. PMID 7706485  1
1995 Dengler R, Emmerich B, Lottspeich F, Oberthiir W, Mast AE. Limited Proteolysis of alpha1Proteinase Inhibitor α1-pi) in Acute Leukemia: Studies on the Resulting Fragments and Implication for the Structure of the Inactivated Inhibitor Biological Chemistry Hoppe-Seyler. 376: 165-172. PMID 7612193 DOI: 10.1515/bchm3.1995.376.3.165  1
1992 Mast AE, Enghild JJ, Salvesen G. Conformation of the reactive site loop of α1-proteinase inhibitor probed by limited proteolysis Biochemistry. 31: 2720-2728. PMID 1547212  1
1991 Potempa J, Fedak D, Dubin A, Mast A, Travis J. Proteolytic inactivation of Α-1-anti-chymotrypsin: Sites of cleavage and generation of chemotactic activity Journal of Biological Chemistry. 266: 21482-21487. PMID 1793458  1
1991 Mast AE, Enghild JJ, Pizzo SV, Salvesen G. Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: Comparison of α1-proteinase inhibitor, α1-antichymotrypsin, antithrombin III, α2-antiplasmin, angiotensinogen, and ovalbumin Biochemistry. 30: 1723-1730. PMID 1704258  1
1990 Mast AE, Salvesen G, Brucato FH, Schnebli HP, Pizzo SV. Polyethylene glycol modification of serpins improves therapeutic potential Biological Chemistry Hoppe-Seyler. 371: 101-109. PMID 2400571  1
1990 Mast AE, Salvesen G, Schnebli HP, Pizzo SV. Evaluation of the rapid plasma elimination of recombinant α1-proteinase inhibitor: Synthesis of polyethylene glycol conjugates with improved therapeutic potential Journal of Laboratory and Clinical Medicine. 116: 58-65. PMID 2376698  1
1988 Pizzo SV, Mast AE, Feldman SR, Salvesen G. In vivo catabolism of α1-antichymotrypsin is mediated by the Serpin receptor which binds α1-proteinase inhibitor, antithrombin III and heparin cofactor II Bba - General Subjects. 967: 158-162. PMID 3263884 DOI: 10.1016/0304-4165(88)90005-0  1
Show low-probability matches.